Two new studies suggest that tests based on Cyclin E or microarray analysis have the potential to outperform conventional criteria predicting the outcome of breast cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A prognostic index for operable, node-negative breast cancer
British Journal of Cancer Open Access 27 April 2004
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Reprinted with permission from NEJM
References
Keyomarsi, K. et al. Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347, 1566–1575 (2002).
Van de Vijver, M.J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 34, 1999–2009 (2002).
van't Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
Bernards, R. & Weinberg, R.A. A progression puzzle. Nature 418, 823 (2002).
Porter, D.C. et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol. Cell. Biol. 21, 6254–6269 (2001).
Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316–322 (2001).
Spruck, C.H., Won, K.A. & Reed, S.I. Deregulated cyclin E induces chromosome instability. Nature 401, 297–300 (1999).
Bermejo, R., Vilaboa, N. & Cales, C. Regulation of CDC6, Geminin, and CDT1 in human cells that undergo polyploidization. Mol. Biol. Cell 13, 3989–4000 (2002).
Payton, M. & Coats, S. Cyclin E2, the cycle continues. Int. J. Biochem. Cell. Biol. 34, 315–320 (2002).
Clark G. In Diseases of the Breast (eds. Harris, J., Lippman, M., Morrow, M. & Hellman, S.) 461–485 (Lippincott-Raven Publishers, Philadelphia, 1996).
Sjostrom, J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol. 41, 334–345 (2002).
Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Gruvberger, S. et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61, 5979–5984 (2001).
Loden, M. et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: Separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21, 4680–4690 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borg, Å., Fernö, M. & Peterson, C. Predicting the future of breast cancer. Nat Med 9, 16–18 (2003). https://doi.org/10.1038/nm0103-16
Issue Date:
DOI: https://doi.org/10.1038/nm0103-16
This article is cited by
-
A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8
Oncogene (2005)
-
Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy
Human Genomics (2004)
-
A prognostic index for operable, node-negative breast cancer
British Journal of Cancer (2004)
-
Cyclin E is a more powerful predictor of breast cancer outcome than proliferation
Nature Medicine (2003)
